It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

31 **Abstract:**

32 The clinical course and severity of COVID-19 vary among patients. This study aimed to 33 investigate the association of the interferon receptor (*IFNAR2*) rs2236757 and oligoadenylate 34 synthetase 3 (*OAS3*) rs10735079 gene polymorphisms with risk of COVID-19 infection and 35 severity among Palestinian patients. The study was conducted between April and May 2021 on 36 154 participants that divided into three groups: the control group (RT-PCR-negative, n=52), the 37 community cases group (RT-PCR-positive, n= 70) and the critically ill cases (ICU group; n=32). 38 Genotyping of the studied polymorphisms was conducted by amplicon-based next-generation 39 sequencing.

40 The genotype distribution of the *IFNAR2* rs2236757 was significantly different among the study 41 groups (P = 0.001), while no significant differences were observed in the distribution of *OAS3* 42 rs10735079 genotypes (P = 0.091). Logistic regression analysis adjusted for possible 43 confounding factors revealed a significant association between the risk allele rs2236757A and 44 critical COVID-19 illness (P < 0.025). Among all patients, the rs2236757GA carriers were more 45 likely to have sore throat $(OR, 2.52 \ (95\% \ CI \ 1.02-6.24); P = 0.011)$; the risk allele rs2236757A 46 was associated with dyspnea (OR, 4.70 (95% CI 1.80-12.27); P < 0.001), while the rs10735079A 47 carriers were less prone to develop muscle aches $(OR, 0.34, 0.95\% \text{ CI } 0.13\text{-}0.88)$; P = 0.0248) and 48 sore throat (OR, 0.17 (95% CI 0.05-0.55); P < 0.001). In conclusion, our results revealed that the 49 rs2236757A variant was associated with critical COVID-19 illness and dyspnea, whereas the 50 rs10735079A variant was protective for muscle aches and sore throat.

51

52 **Key Words**: SARS-CoV-2; COVID-19; SNPs; *OAS3*; *IFNAR2*.

It is made available under a CC-BY 4.0 International license.

54 **Introduction**

55 The Coronavirus disease 2019 (COVID-19) is a respiratory and systemic disease caused by 56 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China, 57 in December 2019 and then rapidly spread across the globe. Worldwide, more than 613 million 58 coronavirus patient was reported with more than 6.5 million of total deaths (Worldometers.info: 59 Dover, Delaware, U.S.A) accessed date 10-09-2022). It is transmitted predominately from person 60 to person mainly through inhalation of small, exhaled respiratory droplets containing infectious 61 virions [1]. The clinical manifestations range from asymptomatic, to severe, life-threatening 62 acute respiratory distress syndrome (ARDS), multi-organ failure, and death [2]. The major 63 symptoms of the disease include fever, cough, fatigue, sore throat, headache, and shortness of 64 breath, with progression to pneumonia [3]. Households are favorable venues for viral 65 transmission, where family members may crowd and be in close contact without following social 66 distancing rules or using masks. Although all household contacts of a positive COVID-19 patient 67 are exposed to the virus, not all get infected.

68 Previous reports showed that male gender, elder age group, and the existence of comorbidities 69 (e.g., cardiovascular, pulmonary, and renal diseases) are risk factors for COVID-19 infection [4]. 70 However, the wide range of the reported symptoms suggested that genetic risk factors may also 71 have a crucial role in disease progression. Although the virus's new mutations have emerged 72 (e.g., UK, South Africa, and India), few studies described the inter-individual genetic differences 73 in the immune response to these new versions of coronavirus.

74 It was reported that variants of the angiotensin converting enzyme 2 (ACE2) gene encode the 75 cellular receptor for SARS-CoV-2 and polymorphisms of serine protease TMPRSS2 affect viral 76 entry and invasion and thus increase COVID-19 severity [5,6]. Moreover, a genome-wide 77 association study (GWAS) conducted in the UK compared the genetic variants in critically ill 78 patients (n= 2244) with severe COVID-19 to variants found in a healthy control group. The study 79 revealed significant associations between the severity of COVID-19 and the genetic variants in 80 five loci including chromosome 3p21.31, spanning the *SLC6A20*, *LZTFL1*, *CCR9*, *FYCO1*, 81 *CXCR6*, and *XCR1* genes; chromosome 12q24.13, in the *OAS* gene cluster; chromosome 82 19p13.2, near tyrosine kinase 2 (TYK2); chromosome 19p13.3, within dipeptidyl peptidase 9 83 (*DPP9*); chromosome 21q22.1, within the interferon receptor gene *INFAR2*. Of these genes,

It is made available under a CC-BY 4.0 International license.

84 *IFNAR2* and *OAS*, are important in the early stages of the disease, whereas the *DPP9*, *TYK2*, and

85 *CCR2* genes drive inflammatory processes in the late stages of critical COVID-19 [7].

86 . It is well-established that SARS-CoV-2 infection activates innate and adaptive immune 87 response, failure of this system and dysregulated massive pro-inflammatory host response would 88 cause harmful tissue damage [8].

89 In this context, the study objective was to investigate the association of four SNPs (*IFNAR2* 90 rs2236757*, DPP9* rs2109069*, OAS3* rs10735079*,* and *LZTFL1* rs73064425 variants), with the 91 susceptibility to COVID-19 infection in Palestinian household contacts and their associations 92 with the clinical manifestations and severity of COVID 19, using amplicon-based next 93 generation sequencing (NGS).

94

95 **Materials and methods**

96 **Study participants**

97 The study participants were recruited from 30 household Palestinian families- living in different 98 cities in the West Bank, Palestine- between April and May 2021. The family was included in the 99 study if it has at least one clinically and laboratory-confirmed COVID-19 case and one 100 laboratory-negative household contact with no COVID-19 symptoms. We divided all family 101 members into two groups: infected cases (community cases group) or uninfected household 102 contacts (control group). An infected case was defined by having a positive RT-PCR test 103 regardless of having symptoms or not and regardless of being a primary or secondary case. An 104 uninfected contact was defined as a family member who had unprotected contact with a positive 105 case, lives at the same place, stayed asymptomatic for ten days after symptoms onset or RT-PCR 106 diagnosis of a positive case; and was tested negative by RT-PCR. Additionally, we consecutively 107 enrolled patients from an intensive care unit (ICU) -at the Palestinian Medical Complex, 108 Ramallah - due to critical COVID-19 illness (ICU cases).

109 We excluded individuals who received COVID-19 vaccination, regardless of the type of the 110 vaccine. Patients' data, including demographic information, symptoms, RT-PCR test result, and 111 comorbidities, were collected via a well-structured questionnaire supervised by health care 112 personnel.

- 113
- 114

It is made available under a CC-BY 4.0 International license.

115 **Sampling, DNA extraction, and genotyping**

116 Blood-sample (five ml) was collected in an EDTA tube from all study participants. The DNA 117 was extracted from each blood sample (200 μl) using a genomic QIAamp DNA purification kit 118 as per the manufacturer's instructions (Qiagen, Hilden, Germany) and kept frozen (-20C) for 119 further analysis. All DNA samples were genotyped for the rs2236757 of *IFNAR2*, rs2109069 of 120 *DPP9*, rs10735079 of *OAS3*, and rs73064425 of the *LZTFL1* gene using amplicon-based NGS 121 (NGS). Briefly, two primers (forward and reverse) were used to target each single nucleotide 122 polymorphism (SNP) as described in Table S1. All primers were modified with over-hanged 123 Illumina adaptor sequences at the 5′ ends (bolded, Table S1), targeting partial sequences of the 124 studied genes. The final product size for each targeted gene was mentioned in Table S1. 125 The PCR product was visualized by 1.5% agarose gel, cleaned by Agencourt AMPure XP system 126 (X1, A63881; Beckman Coulter Genomics, Indianapolis, IN, USA), and eluted into a final

127 volume of 25 μl. All purified samples were amplified by dual indices PCR to barcode each 128 sample using Nextera XT Index Kit (Illumina, San Diego, CA, USA); Five μl from each 129 barcoded sample were pooled together, cleaned again by Agencourt AMPure XP system (X1), 130 and eluted in 50 μl elution buffer. The concentrations of the prepared Libraries were tested by 131 Qubit® Fluorometer (Invitrogen, Carlsbad, CA, USA). A concentration of 4 nM was used with a 132 target of 20k reads for each sample. Deep sequencing was done by NextSeq 500/550 machine

133 using 150-cycle Mid Output Kit (Illumina, San Diego, CA, USA).

134

135 **Bioinformatics and Sequence Analysis**

136 The sequencing data were uploaded to the Galaxy web platform, and we used the public server at 137 "usegalaxy.org" to analyze the obtained DNA sequences [9]. The workflow of filtration included 138 Illumina adaptor trim and quality selection of Q > 20 with a minimal read length of 100 bp. We 139 used eight virtual probe sequences to identify the targeted variants (Table S1). Ultimately, the 140 genotypes were determined based on the ratio between the read counts for wild-type and minor 141 alleles. SNPs were included in the study if they passed our quality measures; Hardy–Weinberg 142 equilibrium (HWE) > 0.05 and genotyping rate > 95%.

143

144

It is made available under a CC-BY 4.0 International license.

146 **Statistical Analysis**

147 We performed the statistical analysis using the SPSS package, version 26.0 (SPSS, Inc., 148 Chicago, IL, USA) and the R environment v.4.1.3. All tests were two-tailed, and we considered 149 P-value < 0.05 significant unless specified. We tested for The Hardy-Weinberg equilibrium 150 (HWE) for all SNPs using the "SNPassoc" package [10]. Moreover, we examined the genetic 151 susceptibility of SARS-CoV-2 and the genetic association with the critical COVID-19 illness by 152 comparing the community patients with the controls, and the ICU patients with the controls, 153 respectively, using five genetic models (co-dominant, dominant, over-dominant, recessive, and 154 additive). Models were adjusted for patient characteristics; age, gender, smoking, history, 155 hypertension, diabetes mellitus, and coronary artery diseases using the "SNPassoc" package. 156 Adjusted odds ratios (ORs) with the associated 95% confidence interval (CI) were calculated for 157 each model. The same models were used to investigate Gene-(Symptoms/Signs) associations. 158 The best model for each SNP was selected using the Akaike information criterion [11].We used 159 Bonferroni correction for multiple comparisons to correct statistical significance ($P < 0.05$, 160 divided by the number of analyzed SNPs) [12,13]. Ultimately, we investigated for any potential 161 gene-gene interaction.

162

163 **Results**

164 **Characteristics of Study Participants**

165 A total of 154 Palestinians were included in this study and divided into three groups; COVID-19 166 infected patients (Community cases group, n=70), uninfected household contacts (Control group, 167 n=52) and critically ill COVID -19 patients (ICU group, n=32). In each group, the median (IQR) 168 age was 28 (27), 24.5 (21.5), and 61 years (27). The characteristics and comorbidities of each 169 study group are shown in Table 1. The median age, the prevalence of smoking, diabetes mellitus 170 (DM), hypertension, and coronary artery disease (CAD) were significantly higher in the ICU 171 group ($P < 0.05$). The clinical characteristics of COVID-19 patients in the community and ICU 172 groups with signs and symptoms frequencies are presented in Table 2. The percentage of 173 symptomatic patients was 93% in the community cases group, whereas 100% in the ICU group. 174 The frequency of fatigability, headache, and loss of taste and/ or smell was significantly higher 175 in the community cases group $(P < 0.05)$. However, dyspnea and cough were more frequent in 176 the ICU group ($P < 0.05$).

It is made available under a CC-BY 4.0 International license.

177 **Genotyping of** *IFNAR2* **rs2236757 and** *OAS3* **rs10735079**

178 The minor allele frequency (MAF) of the *IFNAR2* rs2236757A and the *OAS3* rs10735079A was 179 27% and 50%, respectively. The frequency and genotypes distribution of the *IFNAR2* 180 rs2236757A and the *OAS3* rs10735079A among the three study groups are provided in Table 3. 181 The *IFNAR2* rs2236757 genotypes distribution was significantly variable among the study 182 groups (P = 0.001), while no significant differences were observed in the distribution of *OAS3* 183 rs10735079 genotypes (P = 0.091). The two SNPs; *DPP9* rs2109069, and the *LZTFL1* 184 rs73064425, were excluded from the study due to deviation from the HWE (i.e., $P \le 0.05$) and 185 the low genotyping rate (i.e., $\langle 95\% \rangle$).

186 187

188 *IFNAR2* **rs2236757 and** *OAS3* **rs10735079 polymorphisms and susceptibility to COVID-19** 189 **infection**

190 Logistic regression analysis under five genetic models adjusted for age, sex, smoking history, 191 DM, hypertension, and CAD was used to investigate the role of *IFNAR2* rs2236757 and *OAS3* 192 rs10735079 polymorphisms in the susceptibility of COVID-19 infection and severity, the 193 community cases group was compared to the control group and the ICU group was compared to 194 the control group. As shown in Table 4, none of the studied polymorphisms have a statistically 195 significant association with SARS-CoV-2 infection among community cases ($P > 0.025$) after 196 Bonferroni correction. However, the risk allele rs2236757A of the *IFNAR2* gene was 197 significantly associated with critical COVID-19 illness in all genetic models ($P < 0.025$) except 198 for the recessive $(P = 0.4)$. According to the Akaike information criterion, the dominant model 199 was the best to explain the association (OR, 8.65 (95% CI 1.60-46.68); $P = 0.005$). No 200 significant relationship between the *OAS3* rs10735079 polymorphism and critical COVID-19 201 illness was observed $(P > 0.025$; Table S2).

202

203 **Association of** *IFNAR2* **rs2236757 and** *OAS3* **rs10735079 polymorphisms with COVID-19** 204 **signs and symptoms**

205 Logistic regression analysis under five genetic models adjusted for age, sex, smoking history, 206 DM, hypertension, and CAD was used to investigate the association of *IFNAR2* rs2236757 and

207 *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms.

It is made available under a CC-BY 4.0 International license.

208 For all patients (the community cases group and ICU group), the *IFNAR2* rs2236757 GA carriers 209 were more likely to have a sore throat $(OR, 2.52 (95\% \text{ CI } 951.02-6.24); P = 0.011)$ (Table 5). In 210 addition, patients who developed dyspnea were more likely to have the risk allele rs2236757A; 211 the association was best explained by the additive model (OR, 4.70 (95% CI 1.80-12.27); P < 212 0.001). On the other hand, patients with the risk allele rs10735079A were less prone to develop 213 muscle aches (OR, 0.34 (95% CI 0.13-0.88); P = 0.0248) and sore throat (OR, 0.17 (95% CI 214 0.05-0.55); $P < 0.001$), both associations were best explained by the recessive model (Table 5). 215 Further analysis was performed to compare the community cases group with the control group 216 and the ICU group with the control group as shown in Table 6. None of the community cases 217 group was homozygous for the risk allele *IFNAR2* rs2236757A (Table 6). However, the risk 218 allele rs2236757A was associated with loss of taste or smell (OR, 3.57 (95% CI 1.19-10.72); P = 219 0.019), muscle aches (OR, 3.65 (95% CI 1.12-11.86); P = 0.025), and dyspnea (OR, 4.84 (95% 220 CI 1.45-16.13); $P = 0.006$. We also found that patients with sore throat in the community cases 221 group were unlikely to be homozygous (AA) for the risk allele rs10735079A of *OAS3*; the 222 association was only explained by the recessive model (OR, 0.19 (95% CI 0.05-0.79); $P =$ 223 0.012). Among the ICU group, muscle aches were the only symptoms that had a genetic 224 association; patients with the risk allele rs10735079A were less prone to muscle aches in two 225 models (recessive and additive), and best explained by the additive $(OR, 0.22 (0.05-0.99); P =$ 226 0.014) (Table 6). We tested gene-gene interaction in all models that had a significant association 227 with the clinical manifestations; we did not find a statistically significant interaction between the 228 SNPs. Still, heterozygous rs2236757 (GA) carriers with sore throat were less likely to be 229 homozygous (AA) for the risk allele rs10735079A (OR, 0.06 (95% CI 0.01-0.57)) (data not 230 shown). 231

232

233

234

235

236

237

238

It is made available under a CC-BY 4.0 International license.

239 **Discussion**

240 COVID-19 manifestations are variable among patients, even amongst household members. 241 Before the introduction of the COVID-19 vaccination, 33% of people with SARS-CoV-2 242 infection were reported to be asymptomatic [14]. Wu Z and McGoogan JM reported mild 243 COVID-19 infection in 81% of the patients, severe disease in 14%, and critical illness in 5%[15]. 244 Age, comorbidities, sex, and socioeconomic background play an essential role in COVID-19 245 severity [16–19]. Moreover, novel host genetic factors associated with COVID-19 infection and 246 severity were identified through the collaborated community of human genetics researchers [20]. 247 In the current study, we found that the risk allele *IFNAR2* rs2236757A has a significant 248 association with the critical COVID-19 illness. Such an association was not present for the 249 rs10735079 variant. The rs2236757A variant was found to be related to the critical COVID-19 250 illness in genome-wide significant associations. Additionally, *IFNAR2* has a causal role from a 251 Mendelian randomization result; increased expression of the interferon receptor subunit IFNAR2 252 reduced the odds of severe COVID-19 ($P = 0.0043$) [7]. Type 1 interferons bind IFNAR2, which 253 leads to activation and signal transduction, involving the JAK-STAT pathway [21]. 254 Consequently, this pathway initiates antiviral activity from the target cells and induces apoptosis 255 in infected cells [22]. The role of *IFNAR2* expression was further replicated in other Mendelian 256 randomization studies [23–25]. OAS is a family of antiviral proteins consisting of four members, 257 OAS1, OAS2, OAS3, and OAS-like protein [26]. Both, Interferon and virus infection stimulate 258 the transcription of *OAS* genes in the cell [27,28]. Ribonuclease L is activated through the 259 OAS1- to 3 proteins; products with 2'-5' oligoadenylate synthetase activity. Ribonuclease L 260 activation leads to the degradation of the cellular and viral RNA, resulting in the inhibition of 261 protein synthesis and terminating viral replication [29–31]. The variant rs10735079 lies in the 262 interferon-inducible *OAS* gene cluster (*OAS1*, *OAS2*, and *OAS3*) and was associated with critical 263 COVID-19 illness ($P = 1.65 \times 10^8$) in genome-wide significant associations [7]. However, a 264 similar association was not present in our study.

265 Different symptom clusters have a difference in in-hospital outcomes [32]. Reis et al. reported in 266 a cross-sectional study with nearly 60,000 COVID-19 patients that fever and breathing difficulty 267 increased the chances of hospitalization and death. However, running nose, sore throat, diarrhea, 268 and headache were associated with lower odds of hospitalization and death; they concluded that 269 these symptoms indicate a protective effect [33]. Sadeghifar et al. showed in their binary logistic

It is made available under a CC-BY 4.0 International license.

270 regression model of disease outcome by disease symptoms that shortness of breath and abnormal

271 chest radiographic findings were predictors of higher mortality. Conversely, patients with sore

- 272 throats signified lower mortality [34]. Moreover, Chang et al. indicated that body temperature,
- 273 chills, initial chest X-ray findings, and the presence of diabetes were significant predictors of
- 274 progression to the severe stage of COVID-19 [35].
- 275 Studies that evaluate the role of human genetics in developing the different signs and symptoms 276 of COVID-19 are scarce. Williams et al. studied 3261 same-sex twins to investigate the presence 277 of heritable components in developing the different symptoms of COVID-19. They found 278 heritability elements for delirium, diarrhea, fatigue, anosmia, and meal skipping [36].
- 279 Herein, we investigated the role of the rs2236757 and the rs10735079 variants in developing the 280 different signs and symptoms of COVID-19 in all COVID-19 patients, and in the community 281 patients and ICU patients, separately. Our results indicated that patients with the risk allele 282 rs2236757A were more likely to have dyspnea and sore throat. Among the community patients, 283 the risk allele rs2236757A was found to be associated with dyspnea, loss of taste or smell, and 284 muscle aches. Surprisingly, patients with the risk allele rs10735079A were unlikely to have a 285 sore throat or muscle aches; in particular, the community cases group was less likely to have a 286 sore throat, and the ICU subgroup was less prone to muscle aches. Given that the risk allele 287 rs10735079A was found to be associated with critical COVID-19 illness in multiple previous 288 studies [7,37], the inverse association of the risk allele rs10735079A with having a sore throat 289 might be consistent with Reis et al. and Sadeghifar et al. findings indicating that sore throat 290 might have a protective effect against COVID-19 hospitalization and death [33,34].
- 291 It was reported that Interferon-beta inhibits SARS-CoV-2 virus replication in vitro [38]. 292 However, clinical trials did not reveal a clear benefit from interferon therapy for hospitalized 293 patients with severe COVID-19 [39–42]. Yet, a systematic review of five clinical trials 294 concluded that early administration of Interferon-beta combined with other antiviral drugs is 295 promising [43]. Low expression of *IFNAR2* has a causal role in the progression to critical 296 COVID-19 illness [7]; our study was in line with the Pairo-Castineira et al. study which 297 demonstrated that rs2236757A was associated with the severity of COVID-19 illness [7]. 298 Therefore, a randomized controlled trial that examines the role of interferon therapy in COVID-299 19 patients who have the rs2236757A variant or other reported variants will help to understand 300 the role of interferon therapy and its benefits.

It is made available under a CC-BY 4.0 International license.

301 Our study is limited by the small number of included participants, which was in part due to the 302 newly emerged variants of the SARS-CoV-2 virus; we could not continue recruiting patients 303 when the new SARS-CoV-2 variants became prevalent in Palestine, as different variants may 304 have different manifestations and pathogenesis [44,45]. Moreover, the COVID-19 vaccination 305 was started by the government, which can alter the results. The limited number of patients in the 306 present study may explain the lack of association between the rs10735079 polymorphism and the 307 critical COVID-19 illness. Nonetheless, targeting families strengthen the certainty of adequate 308 exposure to the SARS-CoV-2 virus in the control group. Additionally, the present study is the 309 first in Palestine and one of the few studies that investigated the role of human genetic factors in 310 COVID-19 signs and symptoms. In Conclusion, our study revealed that the *IFNAR2* rs2236757A 311 variant is associated with critical COVID-19 illness. the risk allele rs2236757A was associated 312 with dyspnea and sore throat while patients with the risk allele rs10735079A were unlikely to 313 have a sore throat or muscle aches. Our study may provide preliminary results for further genetic 314 association studies to clarify the role of human genetics in different signs and symptoms of 315 COVID-19 and to enhance our understanding of the pathophysiology of SARS-CoV-2 infection 316 and its complications.

317

318 **Acknowledgements:**

319 The authors would like to thank all the study participants

320

321 **Authors' contributions:**

 SE and AN designed and supervised the experiments, edited and revised the manuscript. MA analyzed the data and wrote the first draft of the manuscript. MA, OA, RA, RS, OM, TH, and ZE extracted the DNA and performed the experiments. AJ involved in patient sampling and data collection. All authors read and approved the final manuscript.

- 326 **Funding**
- 327 This research received no specific grant from any funding agency.
- 328 **Availability of data and materials:**
- 329 Data used in this research are available from the corresponding author on request
- 330
- 331

It is made available under a CC-BY 4.0 International license.

332 **Declarations**

333 **Ethics approval and consent to participate**

- 334 The study procedure was approved by the research ethics committee at Al-Quds University
- 335 (184/REC/2021), with implied consent from all participants.

336 **Competing interests**

- 337 The authors declare that no competing interests exist.
- 338

339 **References:**

- 340 1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease 341 (COVID-19) outbreak. J Autoimmun. 2020;109. doi:10.1016/J.JAUT.2020.102433
- 342 2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: 343 consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395: 344 1033–1034. doi:10.1016/S0140-6736(20)30628-0
- 345 3. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak 346 associated with a new coronavirus of probable bat origin. Nature. 2020;579: 270–273. 347 doi:10.1038/S41586-020-2012-7
- 348 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for 349 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 350 study. The Lancet. 2020;395: 1054–1062. doi:10.1016/S0140-6736(20)30566- 351 3/ATTACHMENT/E61DC4CE-2C32-4FA9-85D7-95911E7D3B94/MMC1.PDF
- 352 5. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the 353 novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. 354 Cell Discovery 2020 6:1. 2020;6: 1–4. doi:10.1038/s41421-020-0147-1
- 355 6. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and 356 expression as candidates to sex and country differences in COVID-19 severity in Italy. 357 Aging. 2020;12: 10087–10098. doi:10.18632/AGING.103415
- 358 7. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. 359 Genetic mechanisms of critical illness in COVID-19. Nature 2020 591:7848. 2020;591: 360 92–98. doi:10.1038/s41586-020-03065-y
- 361 8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected 362 with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497–506. 363 doi:10.1016/S0140-6736(20)30183-5
- 364 9. Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Čech M, et al. The 365 Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 366 update. Nucleic Acids Res. 2016;44: W3–W10. doi:10.1093/NAR/GKW343
- 367 10. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X, et al. SNPassoc: an 368 R package to perform whole genome association studies. Bioinformatics. 2007;23: 654– 369 655. doi:10.1093/BIOINFORMATICS/BTM025
- 370 11. Bozdogan H. Model selection and Akaike's Information Criterion (AIC): The general 371 theory and its analytical extensions. Psychometrika 1987 52:3. 1987;52: 345–370. 372 doi:10.1007/BF02294361

- 373 12. carboni CB-S in onore del professore salvatore ortu, 1935 undefined. Il calcolo delle 374 assicurazioni su gruppi di teste. ci.nii.ac.jp. [cited 16 Jul 2022]. Available: 375 https://ci.nii.ac.jp/naid/20001029336/
- 376 13. Scienze CB-P del RIS di, 1936 undefined. Teoria statistica delle classi e calcolo delle 377 probabilita. cir.nii.ac.jp. [cited 16 Jul 2022]. Available: 378 https://cir.nii.ac.jp/crid/1570009749360424576
- 379 14. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : 380 A Systematic Review. Ann Intern Med. 2021;174: 655–662. doi:10.7326/M20-6976
- 381 15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus 382 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases 383 From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323: 1239– 384 1242. doi:10.1001/JAMA.2020.2648
- 385 16. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the 386 severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20: 387 669–677. doi:10.1016/S1473-3099(20)30243-7
- 388 17. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, el Burai Felix S, et al. 389 Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. 390 MMWR Morb Mortal Wkly Rep. 2020;69: 759–765. doi:10.15585/MMWR.MM6924E2
- 391 18. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. 392 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients 393 Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323: 2052–2059. 394 doi:10.1001/JAMA.2020.6775
- 395 19. Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, et al. Disparities in COVID-19 396 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and 397 Meta-analysis. JAMA Netw Open. 2021;4.
- 398 doi:10.1001/JAMANETWORKOPEN.2021.34147
- 399 20. Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. Mapping the 400 human genetic architecture of COVID-19. Nature 2021 600:7889. 2021;600: 472–477. 401 doi:10.1038/s41586-021-03767-x
- 402 21. Novick D, Cohen B, Rubinstein M. The human interferon αβ receptor: Characterization 403 and molecular cloning. Cell. 1994;77: 391–400. doi:10.1016/0092-8674(94)90154-6
- 404 22. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a 405 multimodal machinery of gene regulation by the IRF family of transcription factors. Curr 406 Opin Immunol. 2002;14: 111–116. doi:10.1016/S0952-7915(01)00305-3
- 407 23. Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, et al. 408 Actionable druggable genome-wide Mendelian randomization identifies repurposing 409 opportunities for COVID-19. Nature Medicine 2021 27:4. 2021;27: 668–676. 410 doi:10.1038/s41591-021-01310-z
- 411 24. Liu D, Yang J, Feng B, Lu W, Zhao C, Li L. Mendelian randomization analysis identified 412 genes pleiotropically associated with the risk and prognosis of COVID-19. Journal of 413 Infection. 2021;82: 126–132. doi:10.1016/J.JINF.2020.11.031
- 414 25. Hernández Cordero AI, Li X, Milne S, Yang CX, Bossé Y, Joubert P, et al. Multi-omics 415 highlights ABO plasma protein as a causal risk factor for COVID-19. Hum Genet. 416 2021;140: 969–979. doi:10.1007/S00439-021-02264-5/FIGURES/3
- 417 26. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. Nat Rev Immunol. 418 2008;8: 559–568. doi:10.1038/NRI2314

- 419 27. P B, M V, D P, M R, J C. Interferon-responsive regulatory elements in the promoter of the 420 human 2',5'-oligo(A) synthetase gene. Mol Cell Biol. 1987;7: 4498–4504. 421 doi:10.1128/MCB.7.12.4498-4504.1987 422 28. Melchjorsen J, Kristiansen H, Christiansen R, Rintahaka J, Matikainen S, Paludan SR, et 423 al. Differential regulation of the OASL and OAS1 genes in response to viral infections. J 424 Interferon Cytokine Res. 2009;29: 199–207. doi:10.1089/JIR.2008.0050 425 29. Baglioni C, Minks MA, Clercq E de. Structural requirements of polynucleotides for the 426 activation of (2' - 5')An polymerase and protein kinase. Nucleic Acids Res. 1981;9: 427 4939–4950. doi:10.1093/NAR/9.19.4939 428 30. Dong B, Silverman RH. A bipartite model of 2-5A-dependent RNase L. J Biol Chem. 429 1997;272: 22236–22242. doi:10.1074/JBC.272.35.22236 430 31. Clemens MJ, Williams BRG. Inhibition of cell-free protein synthesis by pppA2′ p5′ A2′ 431 p5′ A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell. 432 1978;13: 565–572. doi:10.1016/0092-8674(78)90329-X 433 32. Millar JE, Neyton L, Seth S, Dunning J, Merson L, Murthy S, et al. Distinct clinical 434 symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 435 patients in the ISARIC-4C study. Scientific Reports 2022 12:1. 2022;12: 1–13. 436 doi:10.1038/s41598-022-08032-3 437 33. dos Reis EC, Rodrigues P, de Jesus TR, de Freitas Monteiro EL, Virtuoso Junior JS, 438 Bianchi L. Risk of hospitalization and mortality due to COVID-19 in people with obesity: 439 An analysis of data from a Brazilian state. PLoS One. 2022;17. 440 doi:10.1371/JOURNAL.PONE.0263723 441 34. Sadeghifar J, Jalilian H, Momeni K, Delam H, Sheleme T, Rashidi A, et al. Outcome 442 evaluation of COVID-19 infected patients by disease symptoms: a cross-sectional study in 443 Ilam Province, Iran. BMC Infect Dis. 2021;21: 1–5. doi:10.1186/S12879-021-06613- 444 7/TABLES/4 445 35. Chang MC, Park YK, Kim BO, Park D. Risk factors for disease progression in COVID-19 446 patients. BMC Infect Dis. 2020;20: 1–6. doi:10.1186/S12879-020-05144-X/FIGURES/1 447 36. Williams FMK, Freidin MB, Mangino M, Couvreur S, Visconti A, Bowyer RCE, et al. 448 Self-Reported Symptoms of COVID-19, Including Symptoms Most Predictive of SARS-449 CoV-2 Infection, Are Heritable. Twin Res Hum Genet. 2020;23: 316–321. 450 doi:10.1017/THG.2020.85 451 37. Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. Mapping the 452 human genetic architecture of COVID-19. Nature 2021 600:7889. 2021;600: 472–477. 453 doi:10.1038/s41586-021-03767-x 454 38. Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, et al. 455 Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro 456 When Administered After Virus Infection. J Infect Dis. 2020;222: 722–725. 457 doi:10.1093/INFDIS/JIAA350 458 39. H P, R P, AM H-R, MP P, V S, Q AK, et al. Repurposed Antiviral Drugs for Covid-19 - 459 Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384: 497–511. 460 doi:10.1056/NEJMOA2023184 461 40. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et 462 al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment 463 of Severe COVID-19. Antimicrob Agents Chemother. 2020;64. doi:10.1128/AAC.01061- 464 20
	- 14

It is made available under a CC-BY 4.0 International license.

- 465 41. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of 466 interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults 467 with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet 468 Respir Med. 2021;9: 1365–1376. doi:10.1016/S2213-2600(21)00384-2
- 469 42. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and 470 efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 471 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir 472 Med. 2021;9: 196–206. doi:10.1016/S2213-2600(20)30511-7
- 473 43. Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 474 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn
- 475 Schmiedebergs Arch Pharmacol. 2021;394: 829–838. doi:10.1007/S00210-021-02061-X
- 476 44. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom 477 prevalence, duration, and risk of hospital admission in individuals infected with SARS-478 CoV-2 during periods of omicron and delta variant dominance: a prospective
- 479 observational study from the ZOE COVID Study. Lancet. 2022;399: 1618–1624. 480 doi:10.1016/S0140-6736(22)00327-0
- 481 45. Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and 482 decreased pathogenicity. Signal Transduction and Targeted Therapy 2022 7:1. 2022;7: 1– 483 3. doi:10.1038/s41392-022-01009-8

It is made available under a CC-BY 4.0 International license.

Table 1: Baseline characteristics and comorbidities.

† Median [25th -75th percentile]. * P-value was obtained by Independent-Samples Kruskal-Wallis Test. P < 0.05 was considered significant. M, male; F, female; DM, diabetes mellitus; CAD, coronary artery disease; ICU, intensive care unit.

Table 2: Signs and symptoms of COVID-19 in the community cases and the intensive care unit groups

P < 0.05 was considered significant. ICU, intensive care unit.

It is made available under a CC-BY 4.0 International license.

Person's chi-squared test, P < 0.05 was considered significant.

It is made available under a CC-BY 4.0 International license.

† Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant.

Table 5: Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms in all patients

rs2236757 (IFNAR2)		Yes	No	OR (95% CI)	P-value	rs10735079 (OAS3)		Yes	No	OR (95% CI)	P-value
	Codominant †						Codominant				
Sore throat	GG	13	32				GG	15	17	$0.88(0.33-2.38)$ $0.16(0.04-0.58)$	0.004
	GA	23	25	$2.52(1.02-6.24)$	0.011		GA	17	20		
	AA	$\mathbf{0}$	6	$\boldsymbol{0}$			AA	$\overline{4}$	26		
	Dominant						Dominant				
	GG	13	32	$1.98(0.82 - 4.76)$	0.124		GG	15	17	$0.47(0.19-1.16)$	0.099
	$GA+AA$	23	31				GA+AA	21	46		
	Recessive					Sore throat	Recessive †				
	$GG + GA$	36	57	$\mathbf{0}$	0.026		$GG + GA$	32	37	$0.17(0.05-0.55)$	${}_{0.001}$
	AA	$\mathbf{0}$	6				AA	$\overline{4}$	26		
	Over-dominant						Over-dominant				
	$GG+AA$	13	38	$2.89(1.18-7.13)$	0.018		$GG + AA$	19	43	$1.86(0.78-4.45)$	0.162
	GA	23	25				GA	17	20		
	Log-Additive						Log-Additive				
		36	63	$1.25(0.61 - 2.57)$	0.538			36	63	$0.44(0.24-0.79)$	0.004

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.27.22280425;](https://doi.org/10.1101/2022.09.27.22280425) this version posted September 27, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

† Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant

Table 6: Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms in the community patients and ICU patients, separately

It is made available under a CC-BY 4.0 International license.

† Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant.